Aqara Launches Its First Smart Wall Switch for Europe
22.6.2021 11:00:00 EEST | Business Wire | Press release
Aqara, a provider for smart home products, announced the launch of its first smart wall switch targeted for the European market, the Aqara Smart Wall Switch H1 EU. The Wall Switch H1 EU series is Aqara’s first smart wall switch supporting both round European wall boxes and 86 mm square wall boxes. It’s available in Single and Double Rocker versions, as well as in With Neutral and No Neutral versions. Along with the Wall Switch H1 EU, Aqara also introduced the latest Wireless Remote Switch H1 (Double Rocker) to the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210622005459/en/
Aqara Smart Wall Switch H1 EU and Aqara Wireless Switch H1 (Photo: Aqara)
Both the Wall Switch H1 EU and the Wireless Switch H1 support the Zigbee 3.0 protocol with better stability, compatibility, responsiveness and energy efficiency1. Both switches share the award-wining design with a metal frame, which makes the switches more rigid and durable. Moreover, the combination of the Wall Switch H1 EU and the Wireless Switch H1 can be used in a 2-way switch setup without excessive wiring, or to upgrade the existing 2-way setup to a smart one, so that users will be able to control the light or other device from two different places similar to using two hard-wired 2-way switches, or even from any part of the room by voice commands or via local automations.
The Wall Switch H1 EU is compatible with major smart home ecosystems and voice assistants, including Apple HomeKit, Amazon Alexa, Google Assistant, IFTTT, and more2. The availability of With Neutral and No Neutral versions makes it fit almost all homes, while the With Neutral version supports extra features such as power monitoring and overload protection. Other features of the Wall Switch H1 EU include:
- Convert to Wireless Switch Function: The button of the switch can be remapped so that you will get an extra “wireless switch” while the light or other device will be controlled by automations;
- Overheat Protection: Users can be ensured that their homes are safe and secure;
- LED Indicator Behavior Setting: Users can configure the LED indicator via the Aqara Home app, choosing to turn it off completely, turn it on when the switch is on, or vice versa3.
The Wireless Switch H1 is a HomeKit-compatible remote switch to control Aqara devices and other HomeKit accessories or to switch between smart home scenes. It comes with a double rocker, and recognizes 7 configurable actions including single click, double click, long press, and dual-button press. It also supports the High-Speed Click Mode, which reduces the response time down to 50 milliseconds4. The Wireless Switch H1 also features a 5-year battery life, the longest so far among all Aqara battery-powered devices.
The Wall Switch H1 EU and the Wireless Switch H1 are expected to be available in various European and Asian countries via authorized Aqara distributors in the following months. Please check with your regional distributor(s) for product availability.
For more details of the Wall Switch H1 EU and the Wireless Switch H1, please visit our website.
|
1 |
A compatible Zigbee 3.0 Aqara hub (including Hub M1S, Hub M2 and Camera Hub G2H) is required. |
|
|
2 |
Integration with some third-party ecosystems may be unavailable by the time of the launch. |
|
|
3 |
Not all of these options are available for the No Neutral version. |
|
|
4 |
Only single clicks are recognized in the High-Speed Click Mode. |
About Aqara
Founded in 2016, Aqara is a leading smart home provider with offices in New York and Shenzhen. We provide comprehensive smart home products and solutions that are beautifully designed, affordable and easy to use. Our products range from a variety of sensors to switches, curtain controllers, and door locks, and we have opened more than 400 Aqara Home stores globally to provide more personalized smart home solutions.
We continue to expand our global footprint in the United States, EU, Russia, Southeast Asia, Korea and China, and our online devices have covered 192 countries and territories, serving more than 2 million customers. We aspire to bring smart home technology to every household around the world.
For more information, please visit our website and follow our social platforms.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005459/en/
Contact information
For Media Enquiry:
Michell Li
media@aqara.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom